Predictive Oncology (POAI) Peer Comparison

$6.86

$1.38 (25.18%)

As on 14-Jan-2026 09:30EDT

Market cap

$20 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

--

P/B Ratio

1.4

Div. Yield

0 %

Edit

	Predictive Oncology (POAI)	NanoVibronix (NAOV)
Market cap ($ Mln)	20	4
Revenue ($ Mln)	1	3
Net Profit ($ Mln)	-84.33	-3.57
Net Margin (%)	-11,581.34	-133.04
RoE (%)	--	-9.14
Price to Earnings	--	--
Price-To-Book	1.43	0.04

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Predictive Oncology (POAI)	NanoVibronix (NAOV)
Operating Revenue	0.73	2.69
Cost of Revenue	0.36	1.88
Gross Profit	0.80	1.51
Operating Expenses	10.72	10.25
Operating Profit (EBIT)	-10.35	-9.45
Other Income	0.00	0.00
Profit before Tax	-84.01	-7.27
Provision for Tax	0.00	0.12
Profit after Tax (Net Income)	-84.33	-3.57
Minority Interest	0.00	0.00
Consolidated Profit	0.00	0.00

Liabilities ($ Mln)

	Predictive Oncology (POAI)	NanoVibronix (NAOV)
Shareholder's Funds	-77.43	42.46
Minority Interest	0.00	0.00
Non-Current Liabilities	1.08	0.28
Current Liabilities	79.49	11.64
Total Liabilities	4.97	3.63

Assets ($ Mln)

	Predictive Oncology (POAI)	NanoVibronix (NAOV)
Non-Current Assets	2.03	44.37
Current Assets	1.10	10.02
Total Assets	4.97	3.63
Total Debt*	1.70	3.17
Net Current Assets	-78.38	-1.63

Cashflow ($ Mln)

	Predictive Oncology (POAI)	NanoVibronix (NAOV)
Cash From Operating Activities	-11.96	-2.52
Cash Flow from Investing Activities	0.02	0.00
Cash from Financing Activities	3.94	0.00
Net Cash Inflow / Outflow	--	--

Ratios

Profitability Ratios

	Predictive Oncology (POAI)	NanoVibronix (NAOV)
ROCE (%)	-188.78	-156.46
ROE (%)	-302.42	-9.14
ROA (%)	-179.55	-9.76
EBIT Margin (%)	-11,540.36	-259.37
Net Margin (%)	-11,581.34	-133.04
Cash Profit Margin (%)	-0.01	0.00

Growth Ratios

	Predictive Oncology (POAI)	NanoVibronix (NAOV)
Revenue Growth (%)	-47.20	-18.41
EBIT Growth (%)	-534.43	-460.71
Net Profit Growth (%)	-503.68	-15.71
EPS Growth (%)	-3,437.07	-2.21
Book Value Growth (%)	-34,876.37	1,212.06

Valuation Ratios

	Predictive Oncology (POAI)	NanoVibronix (NAOV)
Price / Earnings	-0.37	-0.05
Price / Book Value	-22.07	0.30
Dividend Yield (%)	--	--
EV/EBITDA	-0.57	0.12
Market Cap ($ Cr)	--	--

Solvency Ratios

	Predictive Oncology (POAI)	NanoVibronix (NAOV)
Debt to Equity	0.00	0.00
Short term debt to equity ratio	-0.01	0.07
Current Ratio	0.01	0.86
Quick Ratio	0.01	0.67
Interest Coverage	--	-23.73

Operating Efficiency Ratios

	Predictive Oncology (POAI)	NanoVibronix (NAOV)
Debtors to sales (%)	3.57	9.39
Asset Turnover	0.02	0.07
Receivable days	115.08	49.48
Inventory Days	191.55	856.25
Payable days	547.56	32.18
Cash Conversion Cycle	-240.93	873.55

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly